Philips
(NYSE: PHG)
and Masimo
(Nasdaq: MASI)
today announced an FDA clearance that allows the incorporation of Masimo’s advanced monitoring tech into Philips’ existing high-acuity patient monitors.
The FDA clearance allows the companies to use SedLine brain function monitoring, Regional Oximetry and CO2 measurements in Philips’ patient monitors, IntelliVue MX750 and MX850. This is the latest extension of Masimo and Philips’ ongoing collaboration that will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment.
When integrating the SedLine, O3 and CO2 advanced Masimo measurements into Philips high acuity IntelliVue MX series, clinicians can access and monitor blood saturation in the brain, anesthetic sedation and patient respiratory performance, all from the same monitor. The data can be shared between monitors. These capabilities and metrics will help care providers act decisively while also helping to lower the cost of care by providing a more holistic view of the patient from one system.
“Our work with Masimo has enabled us to forge new paths in continuous monitoring,” said Christoph Pedain, general manager of hospital patient monitoring at Philips. “We’re connecting data and technologies to help arm care providers with the robust information they need to make timely, informed care decisions for their patients.”
Masimo and Philips first established their partnership in 2016. Since then, the two companies have introduced a variety of advanced monitoring capabilities to select IntelliVue MX-series, multi-parameter monitors. Today’s announcement expands to O3 regional oximetry abilities and the SedLine brain function monitoring and CO2 measurement capabilities.
“Combining our expertise in noninvasive monitoring and signal processing technologies with Philips’ expertise in integrated patient monitoring and therapy solutions is a win-win for patients and clinicians alike,” said Jon Coleman, president of worldwide OEM sales and global health at Masimo. “We are proud that Philips has chosen to make our innovative SedLine, O3, and NomoLine technologies available to their customers. We look forward to continuing our partnership with a focus on improving patient outcomes and reducing the cost of care.”
